Yishai Zohar, Gelesis founder
November 3, 2023 11:50 AM EDTUpdated November 3, 08:57 PM
Pharma

As weight loss lead­ers boom, one biotech con­tender aban­dons its quest with Chap­ter 7 liq­ui­da­tion

John Carroll

Editor & Founder

Weight loss drugs were her­ald­ed as one of the biggest in­no­va­tions in bio­phar­ma in 2023, as the GLP-1 con­tenders swelled in­to megablock­busters. But for one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ap­plied Ther­a­peu­tics CEO steps down af­ter rare dis­ease drug re­jec­tion

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times